I de kliniske studier med tocilizumab er der set et hurtigt fald i CRP, erytrocyt - sedimentationsreaktionen (ESR) og serumamyloid A (SAA).
In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed.